Close Menu

Infectious Disease

News on research and diagnostic development for pathogenic diseases.

The pandemic has underscored the importance of "bringing the trial to the patient," a concept that is likely to persist, particularly in precision oncology.

Over the last six months the agency approved 21 cancer treatments for molecularly defined indications compared to 12 during the same period last year and 20 during all of 2019.

The guideline, in effect for three months, gives access to many molecularly informed indications that NICE previously found not cost-effective or that it hasn't yet reviewed.

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.

From changes in trial enrollment to increased flexibility, clinical trials in precision oncology and other fields are feeling the brunt of the ongoing COVID-19 pandemic.

Oct
08
Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.